spacer


Yataro Daigo / Associate Professor / Biosciences
Medical Genome Sciences / / Molecular Medicine, Medical Oncology, Medical Genetics, Genomics, Proteomics
http://www.ims.u-tokyo.ac.jp/nakamura/daigo/emain_daigo.html

Career Summary
1994_1998: Graduate School of Medicine (Yamanashi Medical University)
1996_1998: Research Fellow (University of Tokyo)
1998_1999: JSPS Postdoctoral Research Fellow (University of Tokyo)
1999_2002: JSPS International Fellow (University of Cambridge)
2002_2005: Assistant Professor (University of Tokyo)
2005_present: Associate Professor (University of Tokyo)
Educational Activities
Research Activities
Many genetic alterations associated with development and progression of human diseases including cancers have been reported, but the precise molecular mechanisms remain unclear. As the nature of cancer cells in individual patients is considered to be defined by their protein expression profiles, systematically analyzing these profiles may provide detailed phenotypic and biological information. In this regard, recent progress in genome and proteome technology has enabled us to examine expression profiles of thousands of genes or proteins in a single experiment. We perform comprehensive gene and protein- expression profiles of several cancers by using our original cDNA microarray system containing 32,256 human genes and ESTs, and MALDI-TOF-MS/LC-MSn with high- throughput screening of tissue microarrays to analyze 1,200 cases of archived clinical samples for validation of the potential target proteins. We can also correlate the genome- wide SNP data obtained by our high-throughput genotyping system with clinical phenotypes and the gene/protein expression profile data. We believe that this effort will provide valuable information for eventually identifying diagnostic/predictive biomarkers and novel therapeutic target molecules for human cancers. Some of these achievements are now on-going in clinical trials in collaborative hospitals.
Literature
1) Dunleavy, E.M., et al. HJURP is a Cell-Cycle-Dependent Maintenance and Deposition Factor of CENP-A at Centromeres. Cell 137: 485_497 (2009)
2) Kamatani, Y., et al. Identification of association of genetic variations in HLA-DP locus with chronic hepatitis B in Asian population through genome-wide association study. Nature Genetics 41: 591_595 (2009)
3) Ueda, K., et al. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics 9: 2182_2192 (2009)
4) Takano, A. et al. Identification of Nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 69: 6694_6703 (2009)
5) Moriwaki, K. et al. Deficiency of GMD leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling. Gastroenterology 137: 188-198, 198.e1-2 (2009)
6) Kato, T., et al. Activation of placenta specific transcription factor Distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. Clin Cancer Res 14: 2363_2370 (2008)
7) Kato, T., et al. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 67: 8544_8553 (2007)
8) Ueda, K., et al. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res. 6: 3475_3483 (2007)
9) Hayama, S., et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 66: 10339_10348 (2006)
10) Ishikawa, N., et al. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res. 65: 9176_9184 (2005)
11) Iyer, N. G., et al. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl. Acad. Sci. USA 101: 7386_7391 (2004)
12) Suzuki, C., et al. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res. 63: 7038_7041 (2003)
13) Daigo, Y., et al. Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers: a new approach for the molecular analysis of paraffin-embedded cancer tissue. Am. J. Pathol. 158, 1623_1631 (2001)
14) Gayther, S. A., et al. Truncating mutations of the EP300 acetylase in human cancers. Nature Genetics 24, 300_303 (2000)
15) Daigo, Y., Satoh, S., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of wild-type Axin. Nature Genetics 24, 245_250 (2000)
Other Activities
Additional Posts:
1. 2009-present
Professor, Department of Medical Oncology
Shiga University of Medical Science
2. 2009-present
Visiting Associate Professor, Department of Clinical Oncology
Juntendo University School of Medicine

Academic Societies:
Japanese Cancer Association (JCA Councilor)
Japanese Society of Medical Oncology (JSMO Faculty)
Japanese Board of Cancer Therapy (JBCT Faculty)
Japan Society of Clinical Oncology (JSCO Active Member)
Japan Society of Human Genetics (JSHG Active Member)
American Association for Cancer Research (AACR Active Member)
American Society of Clinical Oncology (ASCO Active Member)
American Society of Human Genetics (ASHG Regular Member)
American Heart Association (AHA ACLS/BLS Provider)

Awards:
2000 Senior Membership (Wolfson College, University of Cambridge)
2001 The Royal Society Research Grant Holder (The Royal Society, UK)
2002 Scholar-in-Training Awards (American Association for Cancer Research)
2005 Incitement Awards of the JSGE (Japanese Society of Gastroenterology)
2005 Incitement Awards of the JCA (Japanese Cancer Association)

Editorial Board:
Cancer Science (Secretary for Editor-in-Chief)
Journal of Biomedicine and Biotechnology (Editor)
World Journal of Gastrointestinal Oncology (Editor)

spacer
Future Plan
We will introduce our sophisticated and integrated cancer genomics strategy for improving
the treatment of cancer and other diseases in patients.
Messages to Students
One for All, All for One.

top